OQRO

Feed News

Explore

Insider trades Fund moves Congressional trades Federal contracts Screener

Yours

Watchlist Alerts Saved Ask Claude or ChatGPT

Create a free account Sign in

OQRO

Search/

Loading…

Director received an award of 197 CYTK shares | OQRO

Home
Insider trades
Cytokinetics
Director received an award of 197 CYTK shares

Insider trades

Insider trade

Director received an award of 197 CYTK shares

Traded Jan 15, 2026 · Filed Jan 16, 2026

CYTCytokineticsCYTK

197
Shares · @ $63.44

Why it stands out

Compensation award — excluded from discretionary-purchase analysis.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Jan 15, 2026
Reporting period: Not applicable
Filed with the SEC: Jan 16, 2026

DirectorGrant / award

Context

Classification

grant award

Code A — grant or award

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001061983-26-000006
Filed / recorded

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Jan 16, 2026, 9:18 PM UTC

Added to OQRO

Oct 6, 2026, 7:14 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

CYTOKINETICS INC

Issuer CIK

1061983

Ticker

CYTK

Reporting person

Edward M. Md Kaye

Relationship

Director

Security

Common Stock

Table

Non-derivative (Table I)

Transaction date

Jan 15, 2026

Transaction code

Shares / units

197

Price per share

$63.44

Acquired / disposed

Acquired (A)

Shares owned after

10,174

Ownership form

Direct

Amendment

Footnotes from the filing

Fully vested shares of common stock received in lieu of cash retainer pursuant to Equity in Lieu of Cash Retainer Option available to members of our Board of Directors.

Around the same time

Andrew CallosEVP, Chief Commercial Officer

Filed 8mo ago

15KShares · @ $23.26

Traded Feb 5 · filed 1 day later

Derivative exercise or conversion — not an open-market buy.

More Official record

Andrew Callos (EVP, Chief Commercial Officer) sold ~$929K of Cytokinetics

Planned saleFiled 8mo ago

Andrew CallosEVP, Chief Commercial Officer

Filed 8mo ago

15KDerivative units

Traded Feb 5 · filed 1 day later

Derivative exercise or conversion — not an open-market buy.

More Official record